BTIG Upgrades AVITA Medical to Buy, Announces $7 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsUpgradesPrice Target
BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Neutral to Buy and announces $7 price target.
BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Neutral to Buy and announces $7 price target.